Back to News
Market Impact: 0.2
Raymond James Initiates Coverage of Odyssey Therapeutics with Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Raymond James initiated coverage of Odyssey Therapeutics with an Outperform recommendation on October 9, 2026. The stock closed at $18.12 on October 8, before the coverage action; the article text is truncated before providing further price context.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ODTX0.60
More News
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- William Blair downgrades Alignment Healthcare stock rating on cost pressures
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- Cramer: Investors selling Apple on latest iPhone 18 report are 'stupid as plywood'
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Is an AI Research Agent?
- Bitcoin's 52% Crash Proves It's a Tech Stock: Here's What That Means for Portfolio Construction